Tezos Foundation and Artist Misan Harriman Unveil First Works in Permanent Art Collection
9.6.2023 18:42:00 EEST | Business Wire | Press release
Today, the Tezos Foundation, which promotes development on the Tezos blockchain, and Misan Harriman, the world-renowned photographer and activist, announced the first presentation of the Tezos Foundation Permanent Art Collection to celebrate artists and creators in the Tezos ecosystem. These works will be on display in a Digital Art Gallery, to be revealed on June 16 on the Collection’s website for public viewing.
The initial presentation is just a fraction of the overall collection of over 2,000 works acquired between May 2022-2023 with a $1.2M USD endowment from the Tezos Foundation to Misan Harriman. Spearheaded by the Tezos Foundation and driven by Harriman, the initiative reflects the diversity of the digital art community in the Tezos ecosystem and showcases works by artists who span five continents and more than two dozen nationalities.
The first online gallery is separated into three rooms - Who We Are, What We Become, and Tracks of Existence - which highlight important themes around digital identity which emerged from research of the overall collection earlier this year. The works showcase themes of solitude and transcendence, with each piece reflecting the artists’ culture, environment, and individual experiences, exploring three intertwined levels of creative digital identity.
“It has been such a great honor curating the Permanent Art Collection for the Tezos Foundation,” said Harriman. “For me, I’ve wanted to see how inclusive the talent pool could be in a collection like this, and I’ve been endlessly amazed by the broad range of storytelling that I’ve seen across all mediums in the Contemporary Art Space. What makes this Permanent Art Collection so unique is that we have artists from Iran, from Argentina, from India, whom I believe would never have been seen, and they now know that their story, their point of view as creators, matters. To plant those seeds at the scale we have done is an extraordinary achievement and, for me, shows the world what blockchain technology, when married with intentionality and purpose, can do in actually changing people’s lives in a borderless world.”
The completion of this first chapter of the Tezos Foundation Permanent Art Collection allows for new perspectives to take hold on the expansive combination of digital artworks. From poetry and photography to generative art and digital sculpture, the collection allows viewers to interpret new themes on a more global, inclusive scale than most other traditional collections across the globe.
“The Tezos Foundation has always had a deep commitment to its community and to elevating the artists who want to share their work with the world,” said Arthur Breitman, co-founder of Tezos. “Misan Harriman’s expertise and creativity allowed us to honor their art in a first-of-its-kind format, and we’re excited to share these pieces with the public.”
Creators in the First Display of the Tezos Foundation Permanent Art Collection
- Amirhfallah - Twitter - Geo Portal, 2022
- Andreasrau X msoriaro - Twitter (andreasrau) Twitter (msoriaro) - Toccata #40, 2022
- Anibal_Ar13 - Twitter - Reading is the refuge, 2021, Disco Nights, 2021
- Bárbara Bezina - Twitter - Vacio Azulado, 2021
- Blessing Atas - Twitter - Lilac Wine, 2022
- Bomfha - Twitter - Supermarket Day, 2021
- Bumbletheb33 - Twitter - Midnight Sonder, 2022
- Caesuras - Twitter - CSRSNT-ZAAI-32-of-64.png, 2021
- Diane Drubay - Twitter - Ardens 1, 2021
- fdilekyurdakul - Twitter - Dusty Journey, 2022
- Gorkem Keser - Twitter - Lux Aeterna, 2022
- I am the Astra - Twitter - The Birth of Venus in Modern Times, 2022
- Juki - Twitter - Drifters, 2021, Dreaming an Apple Tree, 2021
- Karoline Georges - Twitter - Concordia, 2022
- Katya Kanke - Twitter - Lucy, 2016
- Kopfgestaltung - Twitter - It came from the dark, 2022
- La Delmas - Twitter - Nena Trampa N.7, 2021
- Manuel Michael - Twitter - Realm, 2022
- Natalie Shau - Twitter - figure 014, 2022
- Omentejovem - Twitter - UNTITLED, 2021
- Patrick Amadon - Twitter - Static Glitch 2014, 2021
- Sutu - Twitter - Artist Burden, 2022
- Tan-Tan - Twitter - House Made of Glass, 2021, East of Eden, 2022
- Thomas Lin Pedersen - Twitter - Genuary13, 2021
- Tomislav - Twitter - Encounter, 2021
- Violet Forest - Twitter - ♡ Just an AI girl ♡ 37, 2021
- Youngkevarts - Twitter - The Tempest, 2022
- Zancan - Twitter - Lushtemples — Mint, 2021
About The Tezos Foundation
The Tezos Foundation is a Swiss non-profit foundation that supports the development of the Tezos blockchain, an energy-efficient network leveraged by art institutions and artists worldwide for digital art and NFTs. The Foundation is committed to expanding opportunities for digital artists, providing affordable, sustainable, and accessible NFT infrastructure. Artists using Tezos encompass a global community – one that elevates digital artists in all geographies to share their art with the world. For more information, please visit www.tezos.foundation.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230609005280/en/
Contact information
Randall Woods
Senior Vice President, SBS Comms
tezos@sbscomms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
